iBio (NYSE AMERICAN:IBIO) signed a supply agreement for its new cGMP sterile fill-finish services operation with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies.
iBio’s fill-finish operation is housed in its 135,000 square foot contract development manufacturing organization (CDMO) facility located at Bryan, Tex.
Under the accord, iBio will formulate and fill clinical research quantities of one of the customer’s investigational therapies into sterile vials for use in a planned late-stage clinical trial.
“Shortly after our fill-finish services launch at BIO 2019, a first supply agreement with an emerging leader in the gene and cell therapy space was established,” Robert Kay, iBio’s chairman and CEO, said in a statement.
“While we expect our new fill-finish capabilities also will be attractive to our end-to-end CDMO services clients, this first agreement was secured as a stand-alone project and helps validate our ability to work with a variety of cell-based and other biopharmaceutical products in different formats,” he added.
